Subocclusion colique precoce apres traitement d'une maladie de Crohn refractaire active par infliximab.

Adult; Antibodies, Monoclonal/adverse effects; Colonic Diseases/chemically induced; Crohn Disease/drug therapy; Female; Gastrointestinal Agents/adverse effects; Humans; Intestinal Obstruction/chemically induced; Time Factors

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Belaiche, Jacques ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie - Relations académiques et scientifiques (Médecine)

Language :

French

Title :

Subocclusion colique precoce apres traitement d'une maladie de Crohn refractaire active par infliximab.

Alternative titles :

[en] Early obstructive colon after treatment of active refractory Crohn's disease with infliximab

Publication date :

2003

Journal title :

Gastroentérologie Clinique et Biologique

ISSN :

0399-8320

Publisher :

Masson, Paris, France

Volume :

Issue :

Pages :

1045-7

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 November 2009

Statistics

Number of views

145 (4 by ULiège)

Number of downloads

3 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am J Gastroenterol 2000;95:3469-77.
Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, et al. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 2000;95:3490-7.
D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-34.
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
Prajapati DN, Saeian K, Kim JP, Kugathasan S, Knox JF, Emmons J, et al. Symptomatic luminal stricture underlies infliximab non-responder in Crohn's disease (abstract). Gastroenterology 2002;122:A100.
Vassallo R, Matteson E, Thomas CF, Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. Chest 2002;122:1093-6.
Crespo J, Rivero M, Fabrega E, Cayon A, Amado JA, Garcia-Unzeta MT, et al. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002;47:1604-10.
Henri S, Chevillard C, Mergani A, Paris P, Gaudart J, Camilla C, et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol 2002;169:929-36.